The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Aurorex     4-chloro-N-(2-morpholin-4- ylethyl)benzamide

Synonyms: Aurorix, Deprenorm, Feraken, Manerix, Moclamine, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of moclobemide


Psychiatry related information on moclobemide


High impact information on moclobemide


Chemical compound and disease context of moclobemide


Biological context of moclobemide


Anatomical context of moclobemide


Associations of moclobemide with other chemical compounds


Gene context of moclobemide


Analytical, diagnostic and therapeutic context of moclobemide


  1. Hypertension with moclobemide. Laux, G., Philipp, M., Kohnen, R. Lancet (1996) [Pubmed]
  2. Intrahepatic cholestasis associated with moclobemide leading to death. Timmings, P., Lamont, D. Lancet (1996) [Pubmed]
  3. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Gillman, P.K. Biol. Psychiatry (2006) [Pubmed]
  4. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Illi, A., Sundberg, S., Ojala-Karlsson, P., Scheinin, M., Gordin, A. Clin. Pharmacol. Ther. (1996) [Pubmed]
  5. Combined treatment with corticosteroids and moclobemide favors normalization of hypothalamo-pituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: a randomized, double blind trial. Then Bergh, F., Kümpfel, T., Grasser, A., Rupprecht, R., Holsboer, F., Trenkwalder, C. J. Clin. Endocrinol. Metab. (2001) [Pubmed]
  6. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Berlin, I., Saïd, S., Spreux-Varoquaux, O., Launay, J.M., Olivares, R., Millet, V., Lecrubier, Y., Puech, A.J. Clin. Pharmacol. Ther. (1995) [Pubmed]
  7. Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: a study in healthy volunteers. Coquoz, D., Porchet, H.C., Dayer, P. Clin. Pharmacol. Ther. (1993) [Pubmed]
  8. Biological parameters in major depression: effects of paroxetine, viloxazine, moclobemide, and electroconvulsive therapy. Relation to early clinical outcome. Lestra, C., d'Amato, T., Ghaemmaghami, C., Perret-Liaudet, A., Broyer, M., Renaud, B., Dalery, J., Chamba, G. Biol. Psychiatry (1998) [Pubmed]
  9. Moclobemide. An update of its pharmacological properties and therapeutic use. Fulton, B., Benfield, P. Drugs (1996) [Pubmed]
  10. Moclobemide in social phobia. Duffett, R. The British journal of psychiatry : the journal of mental science. (1998) [Pubmed]
  11. Positron emission tomography quantification of [(11)C]-harmine binding to monoamine oxidase-A in the human brain. Ginovart, N., Meyer, J.H., Boovariwala, A., Hussey, D., Rabiner, E.A., Houle, S., Wilson, A.A. J. Cereb. Blood Flow Metab. (2006) [Pubmed]
  12. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Yu, K.S., Yim, D.S., Cho, J.Y., Park, S.S., Park, J.Y., Lee, K.H., Jang, I.J., Yi, S.Y., Bae, K.S., Shin, S.G. Clin. Pharmacol. Ther. (2001) [Pubmed]
  13. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Gram, L.F., Guentert, T.W., Grange, S., Vistisen, K., Brøsen, K. Clin. Pharmacol. Ther. (1995) [Pubmed]
  14. Moclobemide in social phobia: a controlled dose-response trial. Noyes, R., Moroz, G., Davidson, J.R., Liebowitz, M.R., Davidson, A., Siegel, J., Bell, J., Cain, J.W., Curlik, S.M., Kent, T.A., Lydiard, R.B., Mallinger, A.G., Pollack, M.H., Rapaport, M., Rasmussen, S.A., Hedges, D., Schweizer, E., Uhlenhuth, E.H. Journal of clinical psychopharmacology. (1997) [Pubmed]
  15. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Versiani, M., Nardi, A.E., Mundim, F.D., Alves, A.B., Liebowitz, M.R., Amrein, R. The British journal of psychiatry : the journal of mental science. (1992) [Pubmed]
  16. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease. Sieradzan, K., Channon, S., Ramponi, C., Stern, G.M., Lees, A.J., Youdim, M.B. Journal of clinical psychopharmacology. (1995) [Pubmed]
  17. A double-blind comparison of moclobemide and toloxatone in out-patients presenting a major depressive disorder. Lemoine, P., Mirabaud, C. Psychopharmacology (Berl.) (1992) [Pubmed]
  18. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man. Bitsios, P., Langley, R.W., Tavernor, S., Pyykkö, K., Scheinin, M., Szabadi, E., Bradshaw, C.M. British journal of clinical pharmacology. (1998) [Pubmed]
  19. Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome". Dingemanse, J., Wallnöfer, A., Gieschke, R., Guentert, T., Amrein, R. Clin. Pharmacol. Ther. (1998) [Pubmed]
  20. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Berlin, I., Zimmer, R., Cournot, A., Payan, C., Pedarriosse, A.M., Puech, A.J. Clin. Pharmacol. Ther. (1989) [Pubmed]
  21. Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. Schoerlin, M.P., Mayersohn, M., Korn, A., Eggers, H. Clin. Pharmacol. Ther. (1987) [Pubmed]
  22. Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study. Kragh-Sørensen, P., Müller, B., Andersen, J.V., Buch, D., Stage, K.B. Journal of clinical psychopharmacology. (1995) [Pubmed]
  23. CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Köhler, D., Härtter, S., Fuchs, K., Sieghart, W., Hiemke, C. Pharmacogenetics (1997) [Pubmed]
  24. Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway. Chiou, S.H., Ku, H.H., Tsai, T.H., Lin, H.L., Chen, L.H., Chien, C.S., Ho, L.L., Lee, C.H., Chang, Y.L. Br. J. Pharmacol. (2006) [Pubmed]
  25. Differentiation of hippocampal stem cells into functional neurons: evolving our understanding of monoamine oxidase-A inhibition. Egan, C.G. Br. J. Pharmacol. (2006) [Pubmed]
  26. Use of moclobemide in children with attention deficit hyperactivity disorder. Trott, G.E., Friese, H.J., Menzel, M., Nissen, G. Psychopharmacology (Berl.) (1992) [Pubmed]
  27. Enhanced morphine-induced behavioural effects and dopamine release in the nucleus accumbens in a transgenic mouse model of impaired glucocorticoid (type II) receptor function: influence of long-term treatment with the antidepressant moclobemide. Sillaber, I., Montkowski, A., Landgraf, R., Barden, N., Holsboer, F., Spanagel, R. Neuroscience (1998) [Pubmed]
  28. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition. Kan, J.P., Steinberg, R., Mouget-Goniot, C., Worms, P., Bizière, K. J. Pharmacol. Exp. Ther. (1987) [Pubmed]
  29. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. Schoerlin, M.P., Mayersohn, M., Hoevels, B., Eggers, H., Dellenbach, M., Pfefen, J.P. Clin. Pharmacol. Ther. (1991) [Pubmed]
  30. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Lotufo-Neto, F., Trivedi, M., Thase, M.E. Neuropsychopharmacology (1999) [Pubmed]
  31. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. McEnroe, J.D., Fleishaker, J.C. Clinical pharmacokinetics. (2005) [Pubmed]
  32. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. Kennedy, S.H., Eisfeld, B.S., Dickens, S.E., Bacchiochi, J.R., Bagby, R.M. The Journal of clinical psychiatry. (2000) [Pubmed]
  33. Clinical pharmacokinetics of intranasal sumatriptan. Fuseau, E., Petricoul, O., Moore, K.H., Barrow, A., Ibbotson, T. Clinical pharmacokinetics. (2002) [Pubmed]
  34. Treatment of comorbid opiate addiction and attention-deficit hyperactivity disorder (residual type) with moclobemide: a case report. Vaiva, G., De Lenclave, M.B., Bailly, D. Prog. Neuropsychopharmacol. Biol. Psychiatry (2002) [Pubmed]
  35. Characterization of moclobemide N-oxidation in human liver microsomes. Hoskins, J., Shenfield, G., Murray, M., Gross, A. Xenobiotica (2001) [Pubmed]
  36. Moclobemide: therapeutic use and clinical studies. Bonnet, U. CNS drug reviews. (2003) [Pubmed]
  37. The dexamethasone suppression test and treatment outcome in elderly depressed patients participating in a placebo-controlled multicenter trial involving moclobemide and nortriptyline. Kin, N.M., Nair, N.P., Amin, M., Schwartz, G., Ahmed, S.K., Holm, P., Katona, C., Kragh-Sorensen, P., Klitgaard, N., Song, W.Y., West, T.E., Stage, K. Biol. Psychiatry (1997) [Pubmed]
  38. Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. Angst, J., Amrein, R., Stabl, M. Journal of clinical psychopharmacology. (1995) [Pubmed]
  39. Moclobemide safety: monitoring a newly developed product in the 1990s. Hilton, S., Jaber, B., Ruch, R. Journal of clinical psychopharmacology. (1995) [Pubmed]
  40. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Mayersohn, M., Guentert, T.W. Clinical pharmacokinetics. (1995) [Pubmed]
WikiGenes - Universities